A comparison of the pharmacological properties of garden cultivated and muthi market-sold Bowiea volubilis  by Masondo, N.A. et al.
South African Journal of Botany 86 (2013) 135–138
Contents lists available at SciVerse ScienceDirect
South African Journal of Botany
j ourna l homepage: www.e lsev ie r .com/ locate /sa jbShort communication
A comparison of the pharmacological properties of garden cultivated and muthi
market-sold Bowiea volubilis
N.A. Masondo, A.R. Ndhlala, A.O. Aremu, J. Van Staden ⁎, J.F. Finnie
Research Centre for Plant Growth and Development, School of Life Sciences, University of KwaZulu-Natal Pietermaritzburg, Private Bag X01, Scottsville 3209, South Africa⁎ Corresponding author. Tel.: +27 33 2605130; fax: +
E-mail address: rcpgd@ukzn.ac.za (J. Van Staden).
0254-6299/$ – see front matter © 2013 SAAB. Published
http://dx.doi.org/10.1016/j.sajb.2013.02.169a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 August 2012
Received in revised form 30 January 2013
Accepted 19 February 2013
Available online 25 March 2013
Edited by JJM Meyer
Keywords:
Ames test
Antimicrobial
Anti-inﬂammatory
Bowiea volubilis
Conservation
Traditional medicineBiological activities of petroleum ether (PE), dichloromethane (DCM), 70% ethanol (EtOH) and water extracts of
Botanical Garden-grown (BG) and muthi market-sourced (MM) Bowiea volubilis bulbs were compared. Bulb
extracts were subjected to the microdilution technique using ﬁve test organisms for antimicrobial activity
and cyclooxygenase (COX-1 and -2) inhibition as well as the Ames test for potential mutagenicity. Overall,
both the MM and BG bulb extracts demonstrated a comparatively weak antimicrobial potency. The best
minimum inhibitory concentration (MIC: 1.56 mg/ml) was detected in the MM bulb water extract against
Candida albicans. In both MM and BG bulbs, 63% of the extracts, particularly the non-polar solvent extracts,
exhibited a high (>70% inhibition) COX-1 and -2 inhibitory activity. Both MM and BG bulb extracts were not
mutagenic against the Salmonella typhimurium TA98 tester strain. Current ﬁndings indicate the potential
substitution of cultivated B. volubilis bulbs (BG) for the wild population (MM) which is often utilized and
preferred in traditional medicine. Inevitably, this will contribute to the conservation of the species as the strain
on the wild population due to overharvesting will be alleviated.
© 2013 SAAB. Published by Elsevier B.V. All rights reserved.1. Introduction
Bowiea volubilis Harv. Ex Hook. f., known as igibisila in isiZulu is a
member of the family Hyacinthaceae and is widely distributed in
the eastern part of South Africa. B. volubilis is a perennial bulb that
grows up to 15 cm in diameter with the bulb half buried in the
ground. The tuberous bulb is greenish-white in colour without ﬁbrous
outer scales (Van Wyk et al., 2009). The leaves are lanceolate with
small greenish ﬂowers that bloom in Spring producing an unpleasant
smell (Van Wyk et al., 2009).
In traditional medicine, B. volubilis ranks amongst the top 14% of
the most traded medicinal plants in South Africa (Mander, 1998).
The bulbs contain several active cardiac glycosides such as bovogenin
A and the structurally related bufadienolides. Generally, cardiac gly-
cosides increase the force of heart muscle contractions thus constitut-
ing therapeutic beneﬁts in cases of congestive heart failure (Page,
1964). However, the consumption of toxic cardiac glycosides can af-
fect the cardiac rhythm and cause disturbances of atrio-ventricular
conduction, including a complete atrio-ventricular block (Dai et al.,
2011). Nevertheless, B. volubilis bulbs are used in the treatment of
various ailments in traditional medicine. For instance, the bulbs are
made into an infusion and given to pregnant women to assist in deliv-
ery (Hutchings et al., 1996). The crushed bulbs are used to massage
the skin to prevent infections and can be prepared as a lotion for27 33 2605897.
by Elsevier B.V. All rights reservedsore eyes (Van Wyk et al., 2009). A hot mixture of the outer bulb
scales and water is used in the treatment of dropsy (Watt and
Breyer-Brandwijk, 1962). Furthermore, Zulu herbalists prescribe the
bulb for ascites, sterility, cystitis, backache, muscular pain and blad-
der infections (Van Wyk et al., 1997).
In South Africa, the extensive use as well as increasing demand for
medicinal plants in both formal and informal markets apparently re-
main unregulated (Moyo et al., 2011). Even more concerning is that
an estimated 85% of the medicinal plants harvested and widely used
constitute the non-renewable parts such as bulbs, rhizomes and
bark (Mander, 1998). The bulbs of B. volubilis are the most commonly
used part of the species. Owing to over-harvesting, B. volubilis is cur-
rently classiﬁed as a vulnerable species in the southern African Plant
Red Data List (Raimondo et al., 2009). The over-exploitation and
harvesting of several medicinal plants have thus resulted in these
plants becoming endangered and/or extinct (Fennell et al., 2004).
Consequently, researchers have proposed some practical approaches
to counteract the risk of extinction (Makunga et al., 2008). For
instance, Van Staden (1999) postulated that “small-scale farming”
remains a sustainable means for medicinal plant conservation.
Nevertheless, the absence of convincing evidence on the potency of
cultivated medicinal plants remains a physiological bottleneck.
Traditional healers believe that medicinal plants collected from the
wild are more potent than the cultivated ones (Cunningham, 1993).
Globally, there is an increasing interest in the number of studies
focusing on the possible variations or similarities between wild and
cultivated medicinal plants (Szőke et al., 2004; Vogel et al., 2011;.
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2012). The current study aimed at evaluating the suitability of culti-
vated B. volubilis bulbs as an alternative to wild/natural muthi
market-sourced bulbs in terms of their biological activities and safety.
2. Materials and methods
2.1. Plant collection and extraction
Bulbs of B. volubilis (approximately 5-years-old) were collected in
March 2011 from the University of KwaZulu-Natal (UKZN) Botanical
Garden and designated as Garden-grown (BG). Muthi market-
purchased (MM) B. volubilis bulbs were obtained from the Pietermaritz-
burg commercial herbal market, South Africa. The plant was identiﬁed by
Dr C. Potgieter after which a voucher specimen (Masondo 01) was pre-
pared and deposited at the Bews Herbarium, UKZN, Pietermaritzburg,
South Africa.
Both BG and MM bulbs were oven-dried at 50 °C for four days and
ground into ﬁne powders using a Culatti Grinder (Janke and Kunkel
GMGH, Staufen, Germany). Ground materials (5 g) were extracted
sequentially with 100 ml of petroleum ether (PE), dichloromethane
(DCM), 70% ethanol (EtOH) and water in a sonication bath for 1 h.
The bulb extracts were ﬁltered through Whatman No. 1 ﬁlter paper
and concentrated in vacuo at 40 °C using a Buchi rotary evaporator.
The concentrated extracts were dried over a stream of cold air and
the ﬁnal weights were recorded. Resultant yields (%) of the different
extracts are shown in Table 1. For antibacterial, antifungal, and
anti-inﬂammatory assays and the Ames test, the organic solvent and
water extracts were suspended in EtOH (70%) and water,
respectively.
2.2. Biological activity assays
Four bacterial strains (Bacillus subtilis ATCC 6051; Staphylococcus
aureus ATCC 12600; Escherichia coli ATCC 11775; Klebsiella pneumoniae
ATCC 13883) and a fungal strain (Candida albicans ATCC 10231 were
used for the study. The minimum inhibitory concentration (MIC) of the
bulb extracts was evaluated using the antibacterial microdilution
technique according to Eloff (1998) and modiﬁcation for antifungal
activity (Masoko et al., 2007). The details of the assays, controls used
and measurement of MICs were as outlined by Aremu et al. (2010).
Anti-inﬂammatory potential was evaluated using cyclooxygenase-1
and -2 (COX-1 and -2) inhibitory assays as described by Jäger et al.
(1996) and Zschocke and Van Staden (2000), respectively. We used
the same procedures as outlined by Aremu et al. (2010).
The Ames test was used to evaluate the mutagenic effect of the ex-
tracts (Maron and Ames, 1983; Mortelmans and Zeiger, 2000). Extracts
were re-dissolved in EtOH (70%) to obtain three concentrations of 5,
0.5 and 0.05 mg/ml respectively. The assay conducted without S9
metabolic activation followed the outlines by Ndhlala et al. (2010).Table 1
The yield (%) and antimicrobial activity in terms of minimum inhibitory concentration of B
Extract Yield (%) Minimum inhibitory concentration (mg/ml)
Bacillus subtilis Staphylococcus aureus
BG MM BG MM BG MM
PE 0.348 0.386 6.25 6.25 6.25 12.50
DCM 0.716 1.040 6.25 12.50 3.13 6.25
EtOH 4.332 4.934 6.25 6.25 6.25 3.13
Water 1.686 3.726 6.52 12.50 >12.50 >12.50
Neomycin 1.6 × 10−3 0.8 × 10−3
Amphotericin B
PE: Petroleum ether, EtOH: Ethanol, DCM: Dichloromethane.
BG: Botanical Garden-grown and MM: Muthi market-sourced bulb.2.3. Data analysis
For reliable results, the assays were conducted twice with either
two replicates (antimicrobial and anti-inﬂammatory assays) or
three plates (Ames test) at any particular time. The mean ± standard
error of the results was calculated using Graph Pad Prism (version
4.0) statistical software Programme for Windows (GraphPad soft-
ware Inc.).
3. Results and discussion
3.1. Antimicrobial effect
The MICs of both BG and MM B. volubilis bulb extracts were great-
er than 1 mg/ml (Table 1). The best MIC (1.56 mg/ml) was detected
with the MM bulb water extract against C. albicans. A total of 25%
BG and 45% MM bulb extracts had MICs greater than 10 mg/ml.
Amongst the non-polar solvent (PE and DCM) extracts, BG-obtained
bulbs had similar or better antimicrobial activity compared to the
MM bulbs. On the other hand, the majority of the EtOH and water ex-
tracts of MM bulbs were more potent than the BG bulbs. As highlight-
ed by Bairu et al. (2011), the ecotype, age, size and season are some of
the factors which may signiﬁcantly affect the phytochemical
and pharmacological activities of plant species. Along this line, it
was demonstrated that domestication processes and cultivation
conditions increased the antioxidant properties of Turnera diffusa
(Soriano-Melgar et al., 2012). Therefore, cultivation of medicinal
plants can relieve harvest pressure and help meet the increasing
demand for such plants. In the current study, the relative similarity
in MIC value between the BG and MM indicates the potential of culti-
vated B. volubilis in traditional medicine.
Although the plant is reported to be used for various infections,
both BG and MM bulb extracts had MIC values above 1 mg/ml in
the current study. This rather poor antimicrobial activity has been
demonstrated in previous studies by Stafford et al. (2005) and Buwa
and Van Staden (2006). In view of the fact that infectious diseases
are caused by a wide variety of microorganisms, it is possible that
B. volubilis extracts will be effective against other microorganism
not tested in the current study.
3.2. Anti-inﬂammatory effect
Based on a scheme devised by Tunón et al. (1995), four levels of
inhibitory activity are deﬁned: below 20% = “insigniﬁcant”, between
20 and 40% = “low” activity, from 40 to 70% = “moderate” activity,
and above 70% = “high” inhibition. Several studies have shown that
medicinal plants potentially provide a useful source of new effective
anti-inﬂammatory agents (Taylor et al., 2001). In both MM and BG
bulbs, the majority (63%) of the extracts particularly, the non-polar
solvent extract exhibited a high (>70% inhibition) COX-1 and -2
inhibitory activity (Fig. 1). In terms of COX-1 inhibition, more (75%)otanical Garden-grown and muthi market-sourced Bowiea volubilis bulb extracts.
Klebsiella
pneumonia
Escherichia coli Candida albicans
BG MM BG MM BG MM
6.25 6.25 6.25 6.25 12.50 >12.50
12.50 6.25 3.13 3.13 12.50 12.50
6.25 3.13 6.25 6.25 3.13 12.50
6.25 3.13 >12.50 >12.50 3.13 1.56
1.6 × 10−3 0.8 × 10−3
9.8 × 10−3
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than the MM (50%) extract. Conversely for COX-2 inhibition, MM
(75%) extracts were more potent than the BG (50%) extracts. Water
extracts of both MM and BG bulb had an insigniﬁcant inhibitory activ-
ity against COX-2 enzymes. Nevertheless, the MM water extract had
about 7-fold better COX-1 inhibitory activity than the BG bulbs.
Current ﬁndings are in agreement with other studies where it was
demonstrated that non-polar solvent extracts of several South African
medicinal plants generally possess better COX inhibition than the
water extracts (Jäger et al., 1996; Aremu et al., 2010; Bairu et al.,
2011). The better inhibitory activity of the non-polar extracts could
be due to better extraction of the active principles by the extracting
organic solvents (Jäger et al., 1996).
In recent times, focus has been on the production of non-steroidal
anti-inﬂammatory drugs (NSAIDs) which can inhibit COX-2 without
having any adverse effect on COX-1 (Fennell et al., 2004). In addition,
such drugs/compounds have signiﬁcant therapeutic value because
they are non-ulcerogenic and have anti-inﬂammatory activity
(Mantri and Witiak, 1994). In MM EtOH extract, there was a higher
COX-2 inhibition than COX-1 which is an indication that the plant ex-
tract is of better pharmacological potential (Fennell et al., 2004). Gen-
erally, plants with such COX-2 inhibitory activity are preferred in the
search for novel chemicals (Taylor and Van Staden, 2001). Although
pain is known to be caused by several physiological pathways, the in-
hibition of COX-1 and -2 by the extracts (mainly non-polar MM and
BG) is further evidence of the efﬁcacy of B. volubilis against pain and
inﬂammation-related ailments in traditional medicine (Hutchings et
al., 1996). Nevertheless, the effectiveness of both BG and MM B.
volubilis extracts against other enzymes, for example lipoxygenase
(LOX) involved in the LOX pathway may be necessary.Fig. 1. Anti-inﬂammatory activity of Botanical Garden-grown andmuthimarket-sourced Bow
COX-2 enzyme inhibition. C = control (Indomethacin), PE = petroleum ether, DCM = dic3.3. Mutagenic effect
In terms of the number of revertants produced, therewere somedif-
ferences between the MM and BG extracts (Table 2). An estimated 50%
of the MM bulb extracts had a greater number of revertants than the
BG-grown bulbs. For instance, the number of revertants produced in
water extracts of MM bulbs at 0.5 mg/ml was 3-fold higher than that
of BG extracts. Overall, all the extracts of the MM and BG bulbs were
not mutagenic towards the Salmonella typhimurium TA98 tester strain
under the investigated conditions. Furthermore, bacterial toxicity was
evaluated by observing the background lawn of bacterial growth. The
presence of a granular thin ﬁlm layer on the background lawn indicates
the absence of toxicity (Mortelmans and Zeiger, 2000). There was no
toxicity detected in both MM and BG extracts as well as in the controls
against the S. typhimurium tester strain. However, at this stage, the
absence of any toxic or mutagenic effects remains preliminary safety
ﬁndings. Further studies involving the use of more bacterial strains as
well as the mimicking of metabolic activation systems of the body will
be required for a more reliable verdict.
4. Conclusions
For conservation of medicinal plants, the potential of the use of
tissue-cultured and cultivated plantlets has been demonstrated
for species such as Tulbaghia violacea (Ncube et al., 2011) and
Harpagophytum procumbens (Bairu et al., 2011). From the current
study, there was generally no wide variation in the biological activi-
ties between MM and BG extracts. It gives an indication that cultivat-
ed B. volubilis can be used in traditional medicine rather than relying
on bulbs from wild populations. In order to meet the increasingiea volubilis bulb extracts. (A) Percentage COX-1 enzyme inhibition and (B) percentage
hloromethane, EtOH = ethanol, W = water.
Table 2
Mutagenic evaluation of Botanical Garden-grown and muthi market-sourced Bowiea
volubilis bulb extracts in terms of the number of histidine independent (His+) rever-
tants produced per plate using Salmonella typhimurium tester strains (TA98).
Number of His+ revertants
Extract Concentration (mg/ml) Botanical Garden Muthi market
Petroleum ether 5.0 14.0 ± 7.07 18.5 ± 2.12
0.5 14.0 ± 7.07 20.5 ± 0.71
0.05 18.5 ± 4.95 18.5 ± 4.95
Dichloromethane 5.0 15.0 ± 4.24 17.5 ± 3.54
0.5 17.5 ± 4.95 15.5 ± 0.71
0.05 24.0 ± 4.24 16.5 ± 2.12
70% ethanol 5.0 14.5 ± 2.12 14.5 ± 2.12
0.5 19.5 ± 0.71 19.5 ± 0.71
0.05 13.0 ± 1.41 13.0 ± 1.41
Water 5.0 8.0 ± 2.83 21.5 ± 0.71
0.5 8.0 ± 2.83 24.0 ± 4.24
0.05 15.0 ± 5.66 21.0 ± 1.41
4-Nitroquinoline-N-oxide (2 μg/ml) 162.5 ± 2.12 162.5 ± 2.12
Solvent control 16.5 ± 4.95 16.5 ± 4.95
The values are presented as mean ± standard error.
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could possibly consider the option of cultivating this highly-traded
medicinal plant species. The plants are proliﬁc seed producers with
seeds that germinate readily and can be easily cultivated (Kulkarni
et al., 2005). Nevertheless, more in-depth studies to determine the
quality and quantity of the chemical composition in the cultivated
and wild B. volubiliswill be essential. In addition, it will be interesting
to evaluate the possible efﬁcacy of both cultivated and wild
B. volubilis using other pharmacological tests involving both in vitro
and in vivo systems. Stringent studies investigating the efﬁcacy of
tissue-cultured B. volubilis compared to both wild type and cultivated
plants in terms of phytochemical and pharmacological activities are
on-going.
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